Business Context and Reporting Period
Company: Prudential plc (PRU)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended 30 June 2024
Announcement Date: 28 August 2024
Prudential plc, a leading life and health insurer and asset manager operating across Asia and Africa, reported its half-year 2024 results. The period was characterized by resilient performance despite a strong prior-year comparator, regulatory shifts in the Chinese Mainland, and macroeconomic headwinds. The Group continues to execute its 2022-2027 strategy, focusing on new business profit growth and capital efficiency.
Key Financial Metrics
| Metric | Half Year 2024 ($m) | Half Year 2023 ($m) | Change (AER) | Change (CER) |
|---|---|---|---|---|
| New Business Profit | 1,468 | 1,489 | (1)% | 1% |
| New Business Profit (Excl. Economic Impacts) | - | - | - | 8% |
| Adjusted Operating Profit | 1,544 | 1,462 | 6% | 9% |
| Operating Free Surplus Generated (In-force) | 1,351 | 1,438 | (6)% | (4)% |
| Operating Free Surplus Generated (Total) | 983 | 1,024 | (4)% | (2)% |
| IFRS Profit After Tax | 182 | 947 | (81)% | (80)% |
Balance Sheet Highlights (30 June 2024):
- EEV Shareholders' Equity: $43.3 billion (1,575 cents per share), down from $45.3 billion at 31 Dec 2023.
- IFRS Shareholders' Equity: $16.2 billion (588 cents per share).
- Adjusted IFRS Shareholders' Equity: $34.7 billion (1,262 cents per share).
- Free Surplus Ratio: 232% (Target range: 175-200%).
- GWS Capital Surplus over GPCR: $15.2 billion (Cover ratio: 282%).
Material Changes vs. Prior Period
- IFRS Profit Decline: IFRS profit after tax fell 81% to $182 million, primarily due to short-term market fluctuations driven by interest rate movements and a $69 million loss on corporate transactions. Adjusted operating profit, which excludes these fluctuations, grew 9%.
- Non-Controlling Interest Adjustment: A July 2024 Federal Court of Malaysia ruling confirmed the Group's right to acquire a 49% stake in its Malaysian conventional life business but required the recognition of a 49% non-controlling interest. This resulted in a significant adjustment to equity and profit attribution.
- Channel Performance: Agency new business profit declined 12% due to high base effects in 2023 (post-pandemic rebound in Hong Kong) and repositioning in the Chinese Mainland. Conversely, Bancassurance new business profit grew 20% (28% excluding economic impacts), driven by strong performance in Taiwan, Hong Kong, and Singapore.
- Health Business: Health new business profit fell 14% as the Group took decisive action on medical repricing in Indonesia and Malaysia to combat inflation, temporarily impacting sales volumes.
Guidance, Outlook, and Management Commentary
Strategic Outlook: Management remains confident in achieving 2027 financial objectives: a 15-20% compound annual growth rate (CAGR) in new business profit and double-digit CAGR in operating free surplus generated from in-force business (both from a 2022 base). Sales momentum picked up in June and is expected to continue into the second half of 2024.
Capital Management:
- Share Buyback: A $2 billion share buyback program was announced. The first tranche of $700 million is targeted for completion by 27 December 2024. As of 22 August 2024, 22 million shares had been repurchased for $192 million.
- Dividend: A first interim dividend of 6.84 cents per share was declared, a 9% increase year-over-year.
Accounting Methodology Change: Prudential plans to convert from Embedded Value (EEV) to Traditional Embedded Value (TEV) starting in Q1 2025 to improve comparability with peers and reduce economic volatility. This change will lower the reported base for new business profit but does not alter the Group's strategy or capital position.
Risks and Contingencies:
- Geopolitical & Economic: Ongoing tensions (US-China, Middle East) and weak growth in the Chinese Mainland property sector pose risks to asset valuations and sales.
- Regulatory: Increased scrutiny on unlicensed selling practices in Hong Kong and new bancassurance restrictions in Vietnam.
- Medical Inflation: High medical cost inflation in key markets requires continued repricing, which may temporarily suppress sales.
Key Facts for Investor Verification
- Non-Controlling Interest Impact: Verify the specific impact of the Malaysian court ruling on the Group's consolidated equity and profit attribution in future filings.
- TEV Transition: Monitor the Q1 2025 results for the implementation of Traditional Embedded Value (TEV) and the resulting change in reported new business profit baselines.
- Buyback Execution: Track the progress of the $2 billion share buyback program, specifically the completion of the $700 million first tranche by year-end 2024.
- Chinese Mainland Performance: Assess the effectiveness of the business repositioning in the Chinese Mainland (CPL) as regulatory and macroeconomic headwinds persist.
- Health Repricing: Evaluate whether the medical repricing actions in Indonesia and Malaysia successfully stabilize margins without causing long-term erosion in market share.